{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:31:47Z","timestamp":1791923507743,"version":"4.3.4"},"reference-count":151,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Romanian Ministry of Research, Innovation and Digitisation","award":["29 PFE\/30.12.2021"],"award-info":[{"award-number":["29 PFE\/30.12.2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD), once considered a rare disease, is now the most common form of dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate antagonists) are safe but of limited benefit to most patients, offering symptomatic relief without successful cure of the disease. Since the last several decades, there has been a great need for the development of a treatment that might cure the underlying causes of AD and thereby slow its progression in vulnerable individuals. That is why phase I, II, and III studies that act on several fronts, such as cognitive improvement, symptom reduction, and enhancing the basic biology of AD, are imperative to stop the disease. This review discusses current treatment strategies, summarizing the clinical features and pharmacological properties, along with molecular docking analyses of the existing medications.<\/jats:p>","DOI":"10.3390\/cells12010131","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:52:21Z","timestamp":1672282341000},"page":"131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Pharmacotherapy Evolution in Alzheimer\u2019s Disease: Current Framework and Relevant Directions"],"prefix":"10.3390","volume":"12","author":[{"given":"Denisa Claudia","family":"Miculas","sequence":"first","affiliation":[{"name":"Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9898-0753","authenticated-orcid":false,"given":"Paul Andrei","family":"Negru","sequence":"additional","affiliation":[{"name":"Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-1292","authenticated-orcid":false,"given":"Simona Gabriela","family":"Bungau","sequence":"additional","affiliation":[{"name":"Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania"},{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Health Sciences & Technology (SoHST), University of Petroleum and Energy Studies, Bidholi 248007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5188-6540","authenticated-orcid":false,"given":"Syed Shams ul","family":"Hassan","sequence":"additional","affiliation":[{"name":"Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-6592","authenticated-orcid":false,"given":"Delia Mirela","family":"Tit","sequence":"additional","affiliation":[{"name":"Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania"},{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"ref_1","unstructured":"(2022, May 26). Alzheimer\u2019s Disease. Available online: https:\/\/www.alzheimers.org.uk\/about-dementia\/types-dementia\/alzheimers-disease."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/0972-2327.104323","article-title":"Hippocampus in health and disease: An overview","volume":"15","author":"Anand","year":"2012","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_3","unstructured":"(2022, May 27). Basics of Alzheimer\u2019s Disease and Dementia What Is Alzheimer\u2019s Disease?, Available online: https:\/\/www.nia.nih.gov\/health\/what-alzheimers-disease."},{"key":"ref_4","first-page":"CD010803","article-title":"CSF tau and the CSF tau\/ABeta ratio for the diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"3","author":"Ritchie","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_6","unstructured":"Wolfe, M.S. (2018). The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms, Academic Press."},{"key":"ref_7","unstructured":"Vlachakis, D.P. (2018). Has molecular docking ever brought us a medicine?. Molecular Docking, IntechOpen. Available online: https:\/\/www.intechopen.com\/chapters\/59054."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Software News and Update AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_9","first-page":"779","article-title":"BIOVIA Discovery Studio Visualizer","volume":"20","author":"BIOVIA","year":"2017","journal-title":"Softw. Version"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF chimera\u2014A visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Samanta, S., Ramesh, M., and Govindaraju, T. (2022, May 27). Alzheimer\u2019s is a Multifactorial Disease. In Alzheimer\u2019s Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities; Govindaraju T., Ed.; Royal Society of Chemistry; 2022; pp. 1\u201334. Available online: https:\/\/pubs.rsc.org\/en\/content\/chapterhtml\/2022\/bk9781839162305-00001?isbn=978-1-83916-230-5&sercode=bk.","DOI":"10.1039\/9781839162732-00001"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.pu.13.050192.002243","article-title":"Cognitive impairment: Dementia and Alzheimer\u2019s disease","volume":"13","author":"Larson","year":"1992","journal-title":"Annu. Rev. Public Health"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Roy, K. (2018). Computational Modeling of Drugs Against Alzheimer\u2019s Disease, Springer.","DOI":"10.1007\/978-1-4939-7404-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5688\/aj710478","article-title":"Physiology of the autonomic nervous system","volume":"71","author":"McCorry","year":"2007","journal-title":"Am. J. Pharm. Educ."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2174\/1871527313666141023141545","article-title":"Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer\u2019s disease and type 2 diabetes mellitus","volume":"13","author":"Mushtaq","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1021\/jp104258d","article-title":"Catalytic reaction mechanism of acetylcholinesterase determined by Born-Oppenheimer ab initio QM\/MM molecular dynamics simulations","volume":"114","author":"Zhou","year":"2010","journal-title":"J. Phys. Chem. B"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Xu, Y., Cheng, S., Sussman, J.L., Silman, I., and Jiang, H. (2017). Computational Studies on Acetylcholinesterases. Molecules, 22.","DOI":"10.3390\/molecules22081324"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1021\/acs.jcim.9b01073","article-title":"Donepezil Inhibits Acetylcholinesterase via Multiple Binding Modes at Room Temperature","volume":"60","author":"Silva","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Svobodova, B., Mezeiova, E., Hepnarova, V., Hrabinova, M., Muckova, L., Kobrlova, T., Jun, D., Soukup, O., Jimeno, M.L., and Marco-Contelles, J. (2019). Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors. Biomolecules, 9.","DOI":"10.3390\/biom9080379"},{"key":"ref_20","unstructured":"(2022, May 19). Galantamine Derivatives as Acetylcholinesterase Inhibitors: Docking, Design, Synthesis, and Inhibitory Activity. Available online: https:\/\/experiments.springernature.com\/articles\/10.1007\/978-1-4939-7404-7_6."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biosystems.2013.12.002","article-title":"Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer\u2019s agents","volume":"116","author":"Ambure","year":"2014","journal-title":"Biosystems"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"705451","DOI":"10.1155\/2014\/705451","article-title":"Identification of potential herbal inhibitor of acetylcholinesterase associated Alzheimer\u2019s disorders using molecular docking and molecular dynamics simulation","volume":"2014","author":"Seniya","year":"2014","journal-title":"Biochem. Res. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1017\/S1041610218001370","article-title":"Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer\u2019s Disease (AD) in the elderly?","volume":"31","author":"Pinto","year":"2019","journal-title":"Int. Psychogeriatr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13195-021-00930-4","article-title":"Self-Administered Gerocognitive Examination: Longitudinal cohort testing for the early detection of dementia conversion","volume":"13","author":"Scharre","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","article-title":"Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors: A Population-Based Cohort Study","volume":"169","author":"Gill","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1365-2125.1999.00026.x","article-title":"Acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"48","author":"McGleenon","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Waldemar, G., and Burns, A. (2017). Alzheimer\u2019s Disease, Oxford University Press.","DOI":"10.1093\/med\/9780198779803.001.0001"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00115-004-1856-7","article-title":"Nightmares in patients with Alzheimer\u2019s disease caused by donepezil. Therapeutic effect depends on the time of intake","volume":"76","author":"Singer","year":"2005","journal-title":"Nervenarzt"},{"key":"ref_29","unstructured":"Budson, A.E., and Solomon, P.R. (2021). Memory Loss, Alzheimer\u2019s Disease, and Dementia-E-Book: A Practical Guide for Clinicians, Elsevier Health Sciences."},{"key":"ref_30","first-page":"189","article-title":"Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020","volume":"270","author":"Galli","year":"1994","journal-title":"Eur. J. Pharm."},{"key":"ref_31","unstructured":"(2022, May 22). Donepezil. Available online: https:\/\/go.drugbank.com\/drugs\/DB00843."},{"key":"ref_32","unstructured":"Kumar, A., Gupta, V., and Sharma, S. (2022). Donepezil. StatPearls, StatPearls Publishing LLC.. StatPearls Publishing Copyright \u00a9 2022."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1248\/bpb.18.1145","article-title":"Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride (E2020)","volume":"18","author":"Nochi","year":"1995","journal-title":"Biol. Pharm. Bull."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0028-3908(95)00157-3","article-title":"The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex","volume":"35","author":"Giacobini","year":"1996","journal-title":"Neuropharmacology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1254\/jjp.89.7","article-title":"Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor","volume":"89","author":"Sugimoto","year":"2002","journal-title":"Jpn. J. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/j.1552-4604.1993.tb01945.x","article-title":"Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer\u2019s disease, in healthy young and elderly subjects","volume":"33","author":"Ohnishi","year":"1993","journal-title":"J. Clin. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1517\/13543784.6.10.1527","article-title":"Donepezil (E2020): A new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer\u2019s disease","volume":"6","author":"Heydorn","year":"1997","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brainres.2004.11.042","article-title":"Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits","volume":"1033","author":"Geerts","year":"2005","journal-title":"Brain Res."},{"key":"ref_39","first-page":"303","article-title":"Donepezil in Alzheimer\u2019s disease: From conventional trials to pharmacogenetics","volume":"3","author":"Cacabelos","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/WAD.0b013e3181b7642b","article-title":"Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB)","volume":"24","author":"Rosenbloom","year":"2010","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.9740\/mhc.n222761","article-title":"Impact of nighttime donepezil administration on sleep in the older adult population: A retrospective study","volume":"4","author":"Agboton","year":"2014","journal-title":"Ment. Health Clin."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.2004.01848.x","article-title":"The safety and tolerability of donepezil in patients with Alzheimer\u2019s disease","volume":"58","author":"Jackson","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00002512-200825020-00008","article-title":"Safety and tolerability of donepezil at doses up to 20 mg\/day: Results from a pilot study in patients with Alzheimer\u2019s disease","volume":"25","author":"Doody","year":"2008","journal-title":"Drugs Aging"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14656566.2.4.653","article-title":"Review of rivastigmine and its clinical applications in Alzheimer\u2019s disease and related disorders","volume":"2","author":"Desai","year":"2001","journal-title":"Expert Opin. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/(SICI)1096-9861(19980413)393:3<374::AID-CNE8>3.0.CO;2-Z","article-title":"Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation","volume":"393","author":"Darvesh","year":"1998","journal-title":"J. Comp. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","article-title":"Rivastigmine in the treatment of Alzheimer\u2019s disease: An update","volume":"2","author":"Onor","year":"2007","journal-title":"Clin. Interv. Aging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1212\/01.wnl.0000281846.40390.50","article-title":"Pharmacokinetic rationale for the rivastigmine patch","volume":"69","author":"Cummings","year":"2007","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/0091270007312154","article-title":"Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects","volume":"48","author":"Pommier","year":"2008","journal-title":"J. Clin. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/cns.12158","article-title":"A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg\/24 h versus 4.6 mg\/24 h in severe Alzheimer\u2019s dementia","volume":"19","author":"Farlow","year":"2013","journal-title":"CNS Neurosci. Ther."},{"key":"ref_50","first-page":"10.4088","article-title":"Rivastigmine from capsules to patch: Therapeutic advances in the management of Alzheimer\u2019s disease and Parkinson\u2019s disease dementia","volume":"16","author":"Sadowsky","year":"2014","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_51","unstructured":"(2021, May 25). Rivastigmine. Available online: https:\/\/go.drugbank.com\/drugs\/DB00989."},{"key":"ref_52","first-page":"Cd001191","article-title":"Rivastigmine for Alzheimer\u2019s disease","volume":"9","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00002826-200203000-00013","article-title":"Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer\u2019s disease who receive rivastigmine","volume":"25","author":"Jhee","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kudo, T., Davis, K.L., Gonzalez, R.B., and Wilkinson, D.G. (2016). Practical Pharmacology for Alzheimer\u2019s Disease, Springer.","DOI":"10.1007\/978-3-319-26206-2"},{"key":"ref_55","unstructured":"(2022, May 21). Exelon. Available online: https:\/\/www.rxlist.com\/exelon-drug.htm#description."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-009-0075-9","article-title":"Skin tolerability associated with transdermal drug delivery systems: An overview","volume":"26","author":"Ale","year":"2009","journal-title":"Adv. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1517\/17425247.2011.574689","article-title":"Skin tolerability of transdermal patches","volume":"8","author":"Wohlrab","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_58","first-page":"728","article-title":"Pharmacological evaluation of novel Alzheimer\u2019s disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine","volume":"277","author":"Bores","year":"1996","journal-title":"J Pharm. Exp"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/0024-3205(90)90429-U","article-title":"Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo","volume":"46","author":"Thomsen","year":"1990","journal-title":"Life Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/156720509787313961","article-title":"Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients","volume":"6","author":"Nordberg","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/0091270003251853","article-title":"Galantamine population pharmacokinetics in patients with Alzheimer\u2019s disease: Modeling and simulations","volume":"43","author":"Piotrovsky","year":"2003","journal-title":"J. Clin. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2165\/00003088-200342150-00005","article-title":"Clinical pharmacokinetics of galantamine","volume":"42","author":"Farlow","year":"2003","journal-title":"Clin. Pharm."},{"key":"ref_63","unstructured":"(2022, May 20). Galantamine. Available online: https:\/\/go.drugbank.com\/drugs\/DB00674."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/17425251003592137","article-title":"Galantamine for Alzheimer\u2019s disease","volume":"6","author":"Prvulovic","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00002512-200926030-00004","article-title":"Optimal dosing of galantamine in patients with mild or moderate Alzheimer\u2019s disease: Post Hoc analysis of a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Aronson","year":"2009","journal-title":"Drugs Aging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-170672","article-title":"Memantine for the Treatment of Dementia: A Review on its Current and Future Applications","volume":"62","author":"Folch","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00702-014-1180-8","article-title":"Glutamate as a neurotransmitter in the healthy brain","volume":"121","author":"Zhou","year":"2014","journal-title":"J. Neural Transm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-4328(02)00272-3","article-title":"Glutamate receptor function in learning and memory","volume":"140","author":"Riedel","year":"2003","journal-title":"Behav. Brain Res."},{"key":"ref_69","first-page":"18","article-title":"Presynaptic NMDA receptors and spike timing-dependent long-term depression at cortical synapses","volume":"2","author":"Banerjee","year":"2010","journal-title":"Front. Synaptic Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/syn.20472","article-title":"Memantine agonist action at dopamine D2High receptors","volume":"62","author":"Seeman","year":"2008","journal-title":"Synapse"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/gps.4109","article-title":"Memantine improves attention and episodic memory in Parkinson\u2019s disease dementia and dementia with Lewy bodies","volume":"30","author":"Wesnes","year":"2015","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer\u2019s disease","volume":"24","author":"Parsons","year":"2013","journal-title":"Neurotox. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/alzrt160","article-title":"Memantine in patients with Alzheimer\u2019s disease receiving donepezil: New analyses of efficacy and safety for combination therapy","volume":"5","author":"Atri","year":"2013","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Matsunaga, S., Kishi, T., and Iwata, N. (2015). Memantine monotherapy for Alzheimer\u2019s disease: A systematic review and meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123289"},{"key":"ref_75","unstructured":"(2022, May 25). Memantine. Available online: https:\/\/go.drugbank.com\/drugs\/DB01043."},{"key":"ref_76","first-page":"237","article-title":"Update on the use of memantine in Alzheimer\u2019s disease","volume":"5","year":"2009","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_77","first-page":"367","article-title":"Memantine: A review of studies into its safety and efficacy in treating Alzheimer\u2019s disease and other dementias","volume":"4","author":"Thomas","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"ref_78","unstructured":"(2022, May 31). 2870 Studies Found for: Alzheimer, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=alzheimer+&term=&cntry=&state=&city=&dist=%20ongoing%20clinical%20trials."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s disease: Recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: Pharmacology and toxicology","volume":"11","author":"Colovic","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer\u2019s disease: An appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"The Amyloid Cascade Hypothesis in Alzheimer\u2019s Disease: It\u2019s Time to Change Our Mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.npep.2015.06.008","article-title":"Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer\u2019s disease","volume":"52","author":"Barage","year":"2015","journal-title":"Neuropeptides"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Uddin, M.S., Kabir, M.T., Rahman, M.S., Behl, T., Jeandet, P., Ashraf, G.M., Najda, A., Bin-Jumah, M.N., El-Seedi, H.R., and Abdel-Daim, M.M. (2020). Revisiting the Amyloid Cascade Hypothesis: From Anti-A\u03b2 Therapeutics to Auspicious New Ways for Alzheimer\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165858"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fnagi.2019.00256","article-title":"The Evolution of Tau Phosphorylation and Interactions","volume":"11","author":"Trushina","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fneur.2013.00083","article-title":"The importance of tau phosphorylation for neurodegenerative diseases","volume":"4","author":"Noble","year":"2013","journal-title":"Front. Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1007\/s12035-015-9369-x","article-title":"The Role of Cdk5 in Alzheimer\u2019s Disease","volume":"53","author":"Liu","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"104707","DOI":"10.1016\/j.nbd.2019.104707","article-title":"Advances and considerations in AD tau-targeted immunotherapy","volume":"134","author":"Bittar","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_90","first-page":"164","article-title":"Combination therapy for Alzheimer\u2019s disease: Perspectives of the EU\/US CTAD Task Force","volume":"6","author":"Gauthier","year":"2019","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_91","first-page":"575","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Behl, T., Kaur, G., Sehgal, A., Bhardwaj, S., Singh, S., Buhas, C., Judea-Pusta, C., Uivarosan, D., Munteanu, M.A., and Bungau, S. (2021). Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: Pathophysiological and therapeutic perspectives. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031413"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2174\/092986707780597961","article-title":"Microglial activation and its implications in the brain diseases","volume":"14","author":"Dheen","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Behl, T., Kaur, I., Fratila, O., Brata, R., and Bungau, S. (2020). Exploring the potential of therapeutic agents targeted towards mitigating the events associated with amyloid-\u03b2 cascade in Alzheimer\u2019s disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207443"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1007\/s11064-021-03415-w","article-title":"Multifaceted Alzheimer\u2019s Disease: Building a Roadmap for Advancement of Novel Therapies","volume":"46","author":"Kaur","year":"2021","journal-title":"Neurochem. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.2174\/092986711797535245","article-title":"Multi-target-directed ligands in Alzheimer\u2019s disease treatment","volume":"18","author":"Bajda","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1570159X113116660047","article-title":"Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer\u2019s disease","volume":"12","author":"Sollhuber","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/acsptsci.9b00104","article-title":"Molecular pathogenesis and interventional strategies for Alzheimer\u2019s disease: Promises and pitfalls","volume":"3","author":"Bhute","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_99","first-page":"5380346","article-title":"Clinical Trials in Alzheimer\u2019s Disease: A Hurdle in the Path of Remedy","volume":"2020","author":"Oxford","year":"2020","journal-title":"Int. J. Alzheimers Dis."},{"key":"ref_100","first-page":"e12050","article-title":"Alzheimer\u2019s disease drug development pipeline","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref_101","unstructured":"(2022, May 30). Sub-Lingual Dexmedetomidine in Agitation Associated with Dementia (TRANQUILITY), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04251910."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"27950","DOI":"10.3402\/jchimp.v5.27950","article-title":"A new approach to the prevention and treatment of delirium in elderly patients in the intensive care unit","volume":"5","author":"Rosenzweig","year":"2015","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_103","unstructured":"(2022, May 29). MK-1942\/Donepezil Interactions in Participants with Alzheimer\u2019s Disease (MK-1942-005) (DDI), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04308304."},{"key":"ref_104","unstructured":"(2022, May 28). Mycose AdminiStration for HealIng Alzheimer NEuropathy (MASHIANE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04663854."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1900195","DOI":"10.1002\/bies.201900195","article-title":"Trehalose against Alzheimer\u2019s Disease: Insights into a Potential Therapy","volume":"42","author":"Khalifeh","year":"2020","journal-title":"BioEssays"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Benito-Cuesta, I., Ordo\u00f1ez-Gutierrez, L., and Wandosell, F. (2021). Trehalose Reduces the Secreted Beta-Amyloid Levels in Primary Neurons Independently of Autophagy Induction. Metabolites, 11.","DOI":"10.3390\/metabo11070421"},{"key":"ref_107","unstructured":"(2022, May 26). Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients with a-MCI or Vm-AD, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03461276."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"837157","DOI":"10.1155\/2014\/837157","article-title":"Potential Therapeutic Strategies for Alzheimer\u2019s Disease Targeting or Beyond \u03b2-Amyloid: Insights from Clinical Trials","volume":"2014","author":"Jia","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1471-4159.2011.07519.x","article-title":"Proteolytic processing of Alzheimer\u2019s \u03b2-amyloid precursor protein","volume":"120","author":"Zhang","year":"2012","journal-title":"J. Neurochem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: Enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"Vassar","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_111","unstructured":"(2022, May 25). Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease. Available online: https:\/\/investors.alector.com\/node\/7616\/pdf."},{"key":"ref_112","unstructured":"(2022, May 28). ACI-35. Available online: https:\/\/alzheimersnewstoday.com\/aci-35\/."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt237","article-title":"Active immunotherapy options for Alzheimer\u2019s disease","volume":"6","author":"Winblad","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_114","unstructured":"(2022, May 30). THERAPEUTICS, ACI-35. Available online: https:\/\/www.alzforum.org\/therapeutics\/aci-35."},{"key":"ref_115","unstructured":"(2022, May 31). Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer\u2019s Disease. Available online: https:\/\/www.cassavasciences.com\/news-releases\/news-release-details\/cassava-sciences-initiates-phase-3-efficacy-trial-simufilam."},{"key":"ref_116","unstructured":"(2022, May 22). Status of Cassava Sciences New Alzheimer\u2019s Drug: Simufilam. Available online: https:\/\/www.dementiacarecentral.com\/aboutdementia\/treating\/simufilam\/."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e041144","DOI":"10.1002\/alz.041144","article-title":"A single-and multiple-ascending dose study to evaluate the safety and pharmacokinetics of oral PU-AD, an epichaperome inhibitor to treat Alzheimer\u2019s disease: Human\/Trial design","volume":"16","author":"Silverman","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_118","unstructured":"(2022, November 11). Therapeutics, PU-AD. Available online: https:\/\/www.alzforum.org\/therapeutics\/pu-ad."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Silvestro, S., Valeri, A., and Mazzon, E. (2022). Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042011"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1007\/s11033-021-06512-9","article-title":"Recent advances on drug development and emerging therapeutic agents for Alzheimer\u2019s disease","volume":"48","author":"Athar","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_121","unstructured":"(2022, May 19). FDA\u2019s Decision to Approve New Treatment for Alzheimer\u2019s Disease, Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-decision-approve-new-treatment-alzheimers-disease."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer\u2019s disease: Clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_123","unstructured":"(2022, May 29). Effect of CAFfeine on Cognition in Alzheimer\u2019s Disease (CAFCA), Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04570085?term=caffeine&cond=alzheimer&draw=2&rank=1."},{"key":"ref_124","unstructured":"(2022, May 30). #AAIC21\u2014Phase 3 Trial of Anti-Inflammatory NE3107 Begins Enrolling. Available online: https:\/\/alzheimersnewstoday.com\/2021\/08\/12\/aaic21-phase-3-trial-ne3107-therapy-inflammation-insulin-sensitivity-enrolls-1st-patient\/."},{"key":"ref_125","unstructured":"(2022, May 20). A Phase 3 Study of NE3107 in Probable Alzheimer\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04669028."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","article-title":"Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain","volume":"32","author":"Hey","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer\u2019s Disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin Pharm."},{"key":"ref_128","unstructured":"(2022, December 14). Alternative Treatments. Available online: https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/alternative-treatments."},{"key":"ref_129","unstructured":"(2022, December 14). Dietary Supplements, Available online: https:\/\/www.fda.gov\/consumers\/consumer-updates\/dietary-supplements."},{"key":"ref_130","unstructured":"(2022, December 18). Is That Supplement Safe to Take with Your Medications?. Available online: https:\/\/www.alzdiscovery.org\/cognitive-vitality\/blog\/is-that-supplement-safe-to-take-with-your-medications."},{"key":"ref_131","unstructured":"(2022, November 29). Dietary Supplements and Cognitive Function, Dementia, and Alzheimer\u2019s Disease, Available online: https:\/\/www.nccih.nih.gov\/health\/providers\/digest\/dietary-supplements-and-cognitive-function-dementia-and-alzheimers-disease."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Behl, T., Makkar, R., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Bungau, S., Andronie-Cioara, F.L., Munteanu, M.A., and Brisc, M.C. (2021). Current trends in neurodegeneration: Cross talks between oxidative stress, cell death, and inflammation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147432"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6276438","DOI":"10.1155\/2018\/6276438","article-title":"Alleviation of Drugs and Chemicals Toxicity: Biomedical Value of Antioxidants","volume":"2018","author":"Aleya","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2006.02.001","article-title":"Cannabinoids in medicine: A review of their therapeutic potential","volume":"105","year":"2006","journal-title":"J. Ethnopharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Abate, G., Uberti, D., and Tambaro, S. (2021). Potential and Limits of Cannabinoids in Alzheimer\u2019s Disease Therapy. Biology, 10.","DOI":"10.3390\/biology10060542"},{"key":"ref_136","first-page":"37","article-title":"Cannabinoids for treatment of Alzheimer\u2019s disease: Moving toward the clinic","volume":"5","author":"Ferrer","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1007\/s12035-019-1637-8","article-title":"Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer\u2019s Disease","volume":"56","author":"Schubert","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_138","unstructured":"(2022, December 16). Cannabis and Cannabis-Derived Products. Available online: https:\/\/www.alz.org\/media\/documents\/cannabis-and-cannabis-derived-products-statement-updated-feb-2020.pdf."},{"key":"ref_139","unstructured":"(2022, December 17). Music Therapy. Available online: https:\/\/my.clevelandclinic.org\/health\/treatments\/8817-music-therapy."},{"key":"ref_140","unstructured":"(2022, December 11). Art and Music. Available online: https:\/\/www.alz.org\/help-support\/caregiving\/daily-care\/art-music."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fnins.2019.00132","article-title":"Music Intervention Approaches for Alzheimer\u2019s Disease: A Review of the Literature","volume":"13","author":"Leggieri","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmed.2020.00160","article-title":"Music Therapy in the Treatment of Dementia: A Systematic Review and Meta-Analysis","volume":"7","author":"Calero","year":"2020","journal-title":"Front. Med."},{"key":"ref_143","first-page":"300","article-title":"Music therapy and Alzheimer\u2019s disease: Cognitive, psychological, and behavioural effects","volume":"32","year":"2017","journal-title":"Neurologia"},{"key":"ref_144","unstructured":"(2022, December 10). Alternative Treatments for Dementia. Available online: https:\/\/alzheimer.ca\/en\/about-dementia\/how-can-i-treat-dementia\/alternative-treatments-dementia."},{"key":"ref_145","first-page":"Cd004989","article-title":"Massage and touch for dementia","volume":"2006","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_146","first-page":"CD013243","article-title":"Animal-assisted therapy for dementia","volume":"2019","author":"Lai","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3233\/JAD-150692","article-title":"Timely diagnosis for Alzheimer\u2019s disease: A literature review on benefits and challenges","volume":"49","author":"Dubois","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_148","unstructured":"(2022, November 27). Dietary Supplements, Available online: https:\/\/www.fda.gov\/food\/dietary-supplements."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4103\/1673-5374.205108","article-title":"Effects of medicinal plants on Alzheimer\u2019s disease and memory deficits","volume":"12","author":"Akram","year":"2017","journal-title":"Neural Regen. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2174\/19963181MTE0pMzEl3","article-title":"Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases","volume":"20","author":"Akter","year":"2021","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"O\u2019Kelly, J.W. (2016). Music therapy and neuroscience: Opportunities and challenges. Voices A World Forum Music. Ther., 16.","DOI":"10.15845\/voices.v16i2.872"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:54:44Z","timestamp":1760147684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cells12010131"],"URL":"https:\/\/doi.org\/10.3390\/cells12010131","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]}}}